This news from the FDA followed a resubmission after the FDA’s complete response letter for the P2X3 receptor antagonist’s use in refractory chronic cough and unexplained cough.
– Net revenue rose 27% from prior quarter to $74.6 million –– CIMERLI® net sales increased 50% to $40 million compared to prior quarter –– LOQTORZI™ now approved with launch planned for.
Galera Therapeutics (NASDAQ: GRTX) experienced a significant 34% intraday surge on October 18, 2023. This explosive trading has captured the attention of investors, prompting curiosity about the company's efforts to innovate radiotherapy in cancer treatment. Despite the lack of updates on social media, press releases, or SEC filings, this sudden rise has left many intrigued